EUVIMEDEUVIMED entdecken
Fallbericht

Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands

Renaud J S D Heine, Ron H J Mathijssen, Floor A J Verbeek, Chantal Van Gils, Carin A Uyl-de Groot

Value in Health · 2024-10 · 27 (10) · 1367-1372

DOI: 10.1016/j.jval.2024.06.003 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Value in Health, 2024-10. Verfasst von Renaud J S D Heine und 4 weiteren Autor:innen. Beteiligte Einrichtung: Erasmus School of Health Policy and Management (ESHPM), Erasmus University Rotterdam, Rotterdam, The Netherlands; Erasmus Center for Health Economics…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Cost-Benefit Analysis, Quality-Adjusted Life Years, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Managed entry agreements and especially financial-based agreements are commonly used in European countries for innovative cancer pharmaceuticals. These agreements facilitate access to innovative treatments while mitigating financial risks for payers. This study focuses on the confidential price agreement made by the Dutch government for the reimbursement of pembrolizumab, the implications of broadening indications on cost-effectiveness, and the viability or desirability of said agreement. METHODS: We selected 5 indications in which pembrolizumab was deemed effective and developed portioned survival models for each indication. Survival and progression-free survival data from the published trials were utilized to recreate individual patient data, and we extrapolated-using parametric models-to a time horizon of 30 years. Inputs for both quality of life and costs were derived from the available literature and were indexed. RESULTS: The incremental cost-effectiveness ratios ranged between €35 313 and €322 349 per quality-adjusted life-year, depending on the indication. Only 1 indication fell under the €80 000 (or €100 000) cost-effectiveness threshold. When applying the average reported discount on intramural pharmaceuticals in The Netherlands, incremental cost-effectiveness ratios ranged between €20 881 and €252 934 per quality-adjusted life-year gained, and the €80 000 (or €100 000) threshold was met in 3 indications out of 5. CONCLUSIONS: Our results show that pembrolizumab could be cost-effective in some indications, depending on the confidential price agreement established. However, the possibility of reimbursing not cost-effective care when the price is anchored in 1 indication remains possible. Indication-based pricing could help align value and price for innovative pharmaceuticals that are subject to indication broadening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCost-Benefit AnalysisQuality-Adjusted Life YearsAntineoplastic Agents, ImmunologicalHumansNetherlandsDrug CostsQuality of LifeProgression-Free Survival

Stichwörter der Autor:innen

cost-effectivenessmanaged entry agreementspembrolizumabpharmaceutical pricingpricingvalue based pricing

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Erasmus School of Health Policy and Management (ESHPM), Erasmus University Rotterdam, Rotterdam, The Netherlands; Erasmus Center for Health Economics Rotterdam (EsCHER), Erasmus University Rotterdam, Rotterdam, The Neth…
  • Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.
  • Erasmus School of Health Policy and Management (ESHPM), Erasmus University Rotterdam, Rotterdam, The Netherlands.
  • IQVIA, Rotterdam, The Netherlands.

Zitieren

APA

Heine, R. J. S. D., Mathijssen, R. H. J., Verbeek, F. A. J., Van Gils, C., & Uyl-de Groot, C. A. (2024). Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands. Value in Health, 27(10), 1367-1372. https://doi.org/10.1016/j.jval.2024.06.003

Vancouver

Heine RJSD, Mathijssen RHJ, Verbeek FAJ, Van Gils C, Uyl-de Groot CA. Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands. Value in Health. 2024;27(10):1367-1372. doi:10.1016/j.jval.2024.06.003

BibTeX
@article{Heine2024,
  author = {Heine, Renaud J S D and Mathijssen, Ron H J and Verbeek, Floor A J and Van Gils, Chantal and Uyl-de Groot, Carin A},
  title = {Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands},
  journal = {Value in Health},
  year = {2024},
  volume = {27},
  number = {10},
  pages = {1367--1372},
  doi = {10.1016/j.jval.2024.06.003}
}
Kostenlos starten →